SCHEMBL292710

SCHEMBL292710

Clc1nc2c(N3CCCC3)nc(N3CCNCC3)nc2nc1NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 15/20 1.00
PDE4B Q07343 15/20 1.00
PDE4C Q08493 15/20 1.00
PDE4D Q08499 15/20 1.00
ACHE P22303 1/20 0.47
ROCK1 Q13464 1/20 0.45
KHK P50053 1/20 0.45
HTR6 P50406 1/20 0.44
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
CDK5 Q00535 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29824397 1.00 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL291798 0.98 PDE4A (0.96) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL10713846 0.91 PDE4A (0.84) PDE4APDE4BPDE4CPDE4D
SCHEMBL10705672 0.91 PDE4A (0.84) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL10707518 0.90 PDE4A (0.81) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL3539405 0.85 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL5201775 0.85 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL3538019 0.85 PDE4A (0.75) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL11013543 0.84 PDE4A (0.72) PDE4APDE4BPDE4CPDE4DACHE
SCHEMBL10705322 0.83 PDE4A (1.00) PDE4APDE4BPDE4CPDE4DACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2024-09-26 US claimed
EP-4282413-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-11-29 EP claimed
CN-116963773-A Compositions and methods for treating tumors 浙江养生堂天然药物研究所有限公司 2023-10-27 CN claimed
US-20230338345-A1 DRUG COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-10-26 US claimed
EP-4074805-B1 WOOD MATERIAL AND BINDER COMPOSITION AND METHOD FOR PRODUCING A WOOD MATERIAL SWISS KRONO Tec AG (CH) 2023-07-26 EP claimed
EP-3370294-B1 SECONDARY BATTERY AND PREPARATION METHOD THEREFOR REAL POWER INDUSTRIAL LTD COMPANY (CN) 2023-06-28 EP claimed
EP-3315486-B1 METHOD FOR PRODUCING AROMATIC COMPOUND TOSOH CORP (JP) 2023-06-07 EP claimed
EP-4153556-A1 METHOD FOR PREPARING ACRYLIC ACID FROM BETA-PROPIOLACTONE Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) 2023-03-29 EP claimed
EP-3191431-B1 MICRONUTRIENT FERTILIZER SUN CHEMICAL CORP (US) 2023-03-08 EP claimed
EP-4140480-A1 DRUG COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-03-01 EP claimed
WO-2003051344-A1 METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-06-26 WO claimed
US-20020103106-A1 Methods of inducing ovulation MERCK SERONO SA (CH) 2002-08-01 US claimed
EP-0770872-B1 Method for the determination of specific gravity of fluids BAYER AG (US) 2001-01-31 EP claimed
EP-0941256-B1 METHOD FOR PREPARING POLYACRYL(METH)ACRYLATES BASF AG (DE) 2001-01-24 EP claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0745613-B1 Synthesis of silyl-functional telechelic hydrocarbon polymers DOW CORNING (US) 1998-10-14 EP claimed
EP-0510625-B1 Process for preparing hindered amine light stabilizers MONTELL NORTH AMERICA INC (US) 1997-07-02 EP claimed
EP-0469331-B1 Process for preparing organic esters and amides and catalyst system therefor MONTELL NORTH AMERICA INC (US) 1996-09-11 EP claimed
EP-0125554-B1 ION TEST MEANS HAVING A HYDROPHILIC CARRIER MATRIX MILES INC. (US) 1988-07-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS PDE4B, PDE4A, PDE4C PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885
US-20230338345-A1 DRUG COMBINATION AND USE THEREOF PDE4B, PDE4A, ADH4 PDE4A 2/4885PDE4B 1/4885PDE4C 10/4885
US-20020103106-A1 Methods of inducing ovulation PDE4A, PDE4B, PDE4C PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.